1 Min Read
Oct 17 (Reuters) - Contravir Pharmaceuticals Inc
* CMX157 advances head-to-head phase 2A clinical study in Hepatitis B patients with favorable recommendation from DSMB
* Contravir expects to complete remaining two escalation cohorts and report top-line results by year-end 2016.
* Contravir Pharmaceuticals - begun enrolling next dosing group in hephase 2A dose-escalation study comparing safety and efficacy of contravir's CMX157 to tenofovir disoproxil fumarate Source text for Eikon: Further company coverage: